IL235820A0 - Dosage forms comprising apixaban and matrix former - Google Patents

Dosage forms comprising apixaban and matrix former

Info

Publication number
IL235820A0
IL235820A0 IL235820A IL23582014A IL235820A0 IL 235820 A0 IL235820 A0 IL 235820A0 IL 235820 A IL235820 A IL 235820A IL 23582014 A IL23582014 A IL 23582014A IL 235820 A0 IL235820 A0 IL 235820A0
Authority
IL
Israel
Prior art keywords
apixaban
dosage forms
matrix former
former
matrix
Prior art date
Application number
IL235820A
Other languages
Hebrew (he)
Original Assignee
Ratiopharm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ratiopharm Gmbh filed Critical Ratiopharm Gmbh
Publication of IL235820A0 publication Critical patent/IL235820A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
IL235820A 2012-05-24 2014-11-20 Dosage forms comprising apixaban and matrix former IL235820A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201213479549A 2012-05-24 2012-05-24
EP12004041 2012-05-24
PCT/EP2013/001461 WO2013174498A1 (en) 2012-05-24 2013-05-16 Dosage forms comprising apixaban and matrix former

Publications (1)

Publication Number Publication Date
IL235820A0 true IL235820A0 (en) 2015-01-29

Family

ID=54188804

Family Applications (1)

Application Number Title Priority Date Filing Date
IL235820A IL235820A0 (en) 2012-05-24 2014-11-20 Dosage forms comprising apixaban and matrix former

Country Status (5)

Country Link
US (1) US20150272891A1 (en)
EP (1) EP2854759B1 (en)
CA (1) CA2873949A1 (en)
IL (1) IL235820A0 (en)
WO (1) WO2013174498A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104382874A (en) * 2014-11-21 2015-03-04 哈尔滨圣吉药业股份有限公司 Apixaban sustained-release tablets and preparation method thereof
US9603846B2 (en) * 2014-11-25 2017-03-28 Cadila Healthcare Limited Process for the preparation of apixaban
CN104490841B (en) * 2014-12-19 2017-06-30 河南润弘制药股份有限公司 A kind of Apixaban tablet and preparation method thereof
CN105175415A (en) * 2015-10-20 2015-12-23 南京美嘉宁逸医药研究开发有限公司 Preparation method of two-crystal-water-containing H2-2 crystal form of Apixaban
CN108472261B (en) * 2016-01-12 2021-12-03 广东东阳光药业有限公司 Apixaban solid composition and preparation method thereof
EP3195860A1 (en) * 2016-01-22 2017-07-26 STADA Arzneimittel AG Method for producing an apixaban granulate
WO2017163170A1 (en) * 2016-03-21 2017-09-28 Sun Pharmaceutical Industries Limited Pharmaceutical composition comprising apixaban
CN105943536A (en) * 2016-05-06 2016-09-21 杭州容立医药科技有限公司 Preparation method and application of solid dispersion
WO2017221209A1 (en) 2016-06-23 2017-12-28 Lupin Limited Pharmaceutical formulations of apixaban
EP3582777A4 (en) * 2017-02-17 2020-12-23 Unichem Laboratories Ltd Pharmaceutical composition of apixaban
TR201722523A2 (en) 2017-12-28 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi SOLID ORAL PHARMACEUTICAL COMPOSITIONS CONTAINING APIXABAN
CN108904461A (en) * 2018-09-07 2018-11-30 无锡凯夫制药有限公司 A kind of preparation method of Apixaban tablet
EP3669866A1 (en) * 2018-12-19 2020-06-24 KRKA, d.d., Novo mesto Pharmaceutical composition comprising apixaban
EP4251271A1 (en) * 2020-11-27 2023-10-04 Santa Farma Ilac Sanayii A.S. Direct compression method for non-micronised apixaban formulations
AU2022288053A1 (en) * 2021-06-08 2023-12-21 Taho Pharmaceuticals Ltd. Apixaban film product and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL204263B1 (en) 2001-09-21 2009-12-31 Bristol Myers Squibb Co Lactam-containing compounds and derivatives thereof as factor xa inhibitors
JP2006516969A (en) * 2003-01-23 2006-07-13 アモレパシフィック コーポレーション Sustained release preparation and method for producing the same
US7396932B2 (en) 2004-09-28 2008-07-08 Bristol-Myers Squibb Company Process for preparing 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones
US20060160841A1 (en) 2005-01-19 2006-07-20 Chenkou Wei Crystallization via high-shear transformation
CL2007002618A1 (en) * 2006-09-12 2008-03-14 Glaxo Group Ltd PHARMACEUTICAL COMPOSITION OF ORAL MODIFIED RELEASE UNDERSTANDING A MINI-COMPRESSED PLURALITY WITH A DIAMETER LESS THAN 5 MM AND UNDERSTANDING AN XA FACTOR INHIBITOR WITHIN A MATRIX OF ONE OR MORE POLYMERS; PREPARATION PROCEDURE
HUE048542T2 (en) * 2009-06-16 2020-08-28 Pfizer Dosage forms of apixaban
ES2757603T3 (en) * 2010-02-25 2020-04-29 Bristol Myers Squibb Holdings Ireland Apixaban formulations
CN102058889A (en) * 2010-11-05 2011-05-18 王定豪 Dispersible tablet containing anticoagulants and application thereof

Also Published As

Publication number Publication date
CA2873949A1 (en) 2013-11-28
WO2013174498A1 (en) 2013-11-28
EP2854759A1 (en) 2015-04-08
US20150272891A1 (en) 2015-10-01
EP2854759B1 (en) 2019-12-18

Similar Documents

Publication Publication Date Title
IL274988A (en) Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
IL235820A0 (en) Dosage forms comprising apixaban and matrix former
IL252566B (en) Pharmaceutical compositions and methods
HK1202545A1 (en) New diazaspirocycloalkane and azaspirocycloalkane
IL234628A0 (en) Amino-indolyl-substituted imidazolyl-pyrimidines and their use as medicaments
EP2804645A4 (en) Multiple dose vial and method
EP2884984A4 (en) Therapeutic compositions and methods
EP2867209A4 (en) Compounds and therapeutic uses thereof
EP2718283A4 (en) Indazole- and pyrrolopyridine-derivative and pharmaceutical use thereof
EP2875014A4 (en) Anti-mucus drugs and uses therefor
HK1203050A1 (en) Novel dosage and formulation
GB201218012D0 (en) Dosage forms
GB201208315D0 (en) Pharmaceutical methods and compositions
GB201210989D0 (en) Composition and device